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CLINICAL STUDIES OF TESTICULAR TUMOR 1
   一ANALYSIS OF 27 PATIENTS．W工TH SEMINOMA：THE CLINICAL
SIGNIFICANCE OF HCG－P DFuTERMINATION AND OF RETRO－PERITONEAL
        LYMPH NODE DISSECTION FOR STAGE 1 PATIE， NTS一
Taiji rl［lsuKAMpTo， Yoshiaki’KuMAMoTo， Kiyotaka OHMuRA，
       r］］a］ uji TsuNEKAwA and Kiyohito YAMAzAKi
       Fr・m the 1）御伽ent（lf’ Ur・1・g］，＆ψク・r・Medical（］・llege
                （エ）舵・t・r’PrOf y．1（umam・t・）
   Between August， 1968 and March， 1985， we treated 27 patients with testicular seminorna． The
histopathological type was typical seminoma in 28 （85 O／．） and anaplastic seminoma in 4 （150／．）．
Their clinical stages were classified into stage 1 for 17 patients （630／．）， 7 patients （250／，） in II and 3
（120／，） in III．
   Tumor markersS alpha－fetoprotein（AFP）and hu皿an chorionic gonadotropin（hCG一β）， were
deterMined in 16 patients． None of them showed an elevated level of AFP， but 7 （43．8 O／．） had
elevated hCG－B in the peripheral vein． The hCG－P in the spermatic vein on the turnor side was
elevated in 12 out of 14 patients （88．90／o）． The hCG－rs level in the spermatic vein on the tumor
side Was signi，ficantly higher than that in the peripheral vein in 10 patients with stage 1 semino－
ma． This finding suggests that the determination of hCG－P in the spermatic vein would give us more
accur’≠狽?info．rmatign on the production of hCG－P in seminoma．
   Although the elevation of the hCG－B level in pure seminoma has’been supposed to・be a
poor prbgnostic factor， our tesults indiCated that a mild to moderate elevation of hCG－S in stage
I seminoma did not always imply a poor clinical course， flrst， because none of these 10 patiehts，．
even with an eleyated hCG－P， who underwent rettOperieoneal lymph node dissection （・RPLND）， had
microscopic metastasis， and second， because none of these have had a recurrence of the disease up to
now．
   RPLND did not seem necessary for any of the patients with stage 1 seminoma， since RPLND for
10 such patients revealed no microscopic metastasis and the two treatment regimens， radical orchi－
ectomy followed by RPLND with Post－surgical radiation and radical orchiectomy followed by radia一
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tion alonei．gaye no difference in th6 recurrence rate of the disease．
 一’ For patients of stage II with bulky metastasis in the retroperitoneal space （IIB） and stage III，
the intensive chemotherapy of PVB（Pe）A was effective in two patients． This chemotherapY regi－
men maygive us ． better results for・such patie4ts than the previously used cheMotherapeutic agents
with radiati．on therapy．
’Key words： Seminoma，’ hCG－P， ’Retroperitoneal lyrpph’node dissection， Survival rate
は じ め に













































O’1 stage 1 46．6％， stage II 10．0％， stage III
43．4％であったことと比較すると，stage Iの割合が
多い結果であった，
Tabie 1．’@Histology and stage of 27 patients with seminoma
Histology
of primary lesion． Stage I  Stage I工A   工IBStage IIIB
．（1）Unilateral
  Typical seminoma
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11 1 亘 II
Tumorside ●「umorside3    Normal side
8／10  4／10
（80．0％｝ （40，0％）
（＊ No． of Pts． with elevated marker／No． of pts． examined）
    Normal side
4／4 3／3
（100％） （100％1






Tumor side Normal side
       Peripheral ’Spermatic vein       vein
 Mean±SD． 1．0±1．2 3．2±2．8 O．8±O．6
        Lpく。．05」Lpく。．05」
Fig． 2． HCG－P level simultaneously determined
    both of peripheral and of spermatic
    venous blood in IO patients with stage
    I seminoma．
 2）SeminomaにおけるAFP， hCG一β（Fig．
1， Table 2）
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．Table 2． Frequency of elevated hCG一βlevel of periphcral and of spermatic
         venous blood on tumor side （10 stage 1 seminoma patients with




     blood  elevated ． normal（＞ 0。8 ng／m1）  （く 0．8 ng／m1）
Total
elevated （〉 O．8 ng／ml）







Tota1 3（30．0） 7（70．0）’ 10（10Q）
（ ）：7e
Table 3． Initial treatment regiments for 27 patients with seminoma
（1）Treatments for un．treated casesStage．1Stage 工IAIIB． Stage III
Orchiectomysc only
Orchiectomy ＋ XRT
Orchiectomy ＋ XRT ＋ Chemotherapy
Orchiectomy ＋ Chemotherapy ＋ RPLND
Orchiectomy ＋ RPLND ＋ XRT
Orchiectomy ＋ RPLND ＋ Chemotherapy
















Tota1 17 5 2 3
   （Qrchiectorny：Radical’orchiectomy， XRT：Radiation， RPLND：Retroperitoneal
   lymph node dissection）
一 The patient refused further treatrnent．
eeee Treatment for the patient with recurrence， who had previously received
   radical orchiectomy．
一ve＋ ［［］reatment for the patient with recurrence， who had previously rec’eived













  （A）Stage I seminomaに対する治療法と治療成
績．．




















of hCG一βin spermatic ● ●venous bbod
Normal range






          （ ）： No． of pts．
FigL 3． HCG－P level of spermatic venous blood on tumor
    side and retroperitoneal lymph node metastasis ’in
    IO patients with seminoma received retroperitoneal
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Fig． 4． Survival rate of 27 patients with seminoma．
（KaplanLMeier’s method）
（One patient in stage II was excluded since
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Treatment regimens and recurrence in 17 patients with stage I
semlnoma according to pre－treatment hCG一β1cvel of spermatic
venous blood on tumor side
Pre－treatment hCG一 level of spermatic venous
bloocl on tumor side
Treatment elevatedes normal一 not determined total
Orchiectomy 十 XRT
Orchiectomy ＋ RPLND ＋ XRT
O／2 o





 （Orchiectomy：Radical orchiectomy， XRT：Radiation，
 lymph node dissection）
一 elevated：〉 O．8 ng／ml， normal：〈 O．8 ng／ml








 （B）Stage II seminomaに対する治療法と治療
成績（Fig．4， Table 3）．
 Stage II seminomaは7か月少数であった．この
























 （C）Stage III seminomaに対する治療法と治療
成績（Fig．4， Tablc 3）．
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